S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IDXG · INTERPACE BIOSCIENCES INC
OTC MARKETS - BOATS Real Time Price • USD
$8.68
● At close: May 2 at 4:00:00 PM EDT
$8.68
+0.00
(+0.00%)
Overnight:
6:48:54 AM EDT
52-WEEK RANGE
$8.68
$1.45
$12.00
What's happening
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2023-04-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IDXG
-13.82%
vs S&P 500
-26.03%
1-YEAR RETURN
IDXG
-23.64%
vs S&P 500
-32.55%
6-MONTH RETURN
IDXG
-46.89%
3-MONTH RETURN
IDXG
-34.57%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2023-07-26 (Q2 2023)
$0.09
Est. $—
2022-10-26 (Q3 2022)
$-16.75
Est. $-1.27
MISS -1213.7%
2022-07-26 (Q2 2022)
$-4.65
Est. $-2.65
MISS -75.3%
2022-04-26 (Q1 2022)
$-2.80
Est. $-4.08
BEAT +31.4%
Valuation Measures & Ratios
Enterprise Value4$28.6M
Forward P/E5—
PEG Ratio60.02
Price / Sales (TTM1)0.87
Price / Book71.94
EV4 / Revenue0.79
EV4 / EBITDA6.16
Profit Margin67.64%
Operating Margin11.53%
Return on Equity (ROE8)102.79%
Return on Assets (ROA9)85.91%
Avg Volume (3M)1,830
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2
Change from Prior Settlement+0.00%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Net profit margin is 67.6%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -1.1% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is -23.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IDXG
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $9.0M | $8.8M | $9.2M | $11.5M | $12.3M | $12.0M | $10.2M |
| Gross profit | $5.7M | $5.9M | $5.4M | $5.3M | $7.4M | $7.9M | $7.8M | $6.3M |
| Operating income | $321.0K | $1.1M | $1.1M | -$468.0K | $1.8M | $2.3M | $2.6M | $1.1M |
| Net income | $158.0K | $721.0K | $911.0K | -$640.0K | $1.6M | $1.7M | $2.4M | $708.0K |
| EPS (diluted) | $0.01 | $0.03 | $0.03 | $-0.14 | $0.06 | $0.38 | $0.55 | $0.16 |
| EPS (basic) | $0.01 | $0.03 | $0.21 | $-0.14 | $0.37 | $0.38 | $0.56 | $0.16 |
| Operating margin | $4 | $12 | $13 | -$5 | $16 | $19 | $22 | $11 |
| Net margin | $2 | $8 | $10 | -$7 | $14 | $14 | $20 | $7 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Nov '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $34.5M | $33.4M | $33.8M | — | $12.0M | $12.3M | $14.5M | $14.8M |
| Total liabilities | $11.3M | $10.3M | $11.5M | — | $12.3M | $13.5M | $15.1M | $17.0M |
| Stockholders' equity | $23.2M | $23.1M | $22.4M | — | -$298.0K | -$1.2M | -$582.0K | -$2.2M |
| Total current assets | $11.0M | $10.0M | $9.9M | — | $9.1M | $9.5M | $11.7M | $11.8M |
| Total current liabilities | $5.0M | $4.0M | $5.1M | — | $5.9M | $7.1M | $8.7M | $10.6M |
| Cash & equivalents | $2.7M | $2.6M | $2.5M | $2.1M | $1.4M | $502.0K | $1.2M | $1.5M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $6.3M | $5.9M | $5.6M | — | $6.0M | $7.2M | $8.8M | $8.5M |
| Inventory | $1.1M | $961.0K | $1.1M | — | $1.1M | $973.0K | $1.2M | $1.2M |
| Other current assets | $2.0M | $1.4M | $1.7M | — | $1.7M | $1.8M | $1.7M | $1.8M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $1.6M | $1.3M | $1.4M | — | $1.5M | $1.4M | $1.3M | $1.4M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $44.0K | $44.0K | $44.0K | — | $45.0K | $45.0K | $45.0K | $45.0K |
| Accounts payable | $1.6M | $805.0K | $983.0K | — | $1.4M | $1.2M | $1.7M | $1.7M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $5.8M | $5.7M | $5.6M | — | $5.5M | $5.4M | $5.3M | $5.2M |
| Common stock & paid-in capital | $640.0K | $640.0K | $407.0K | — | $407.0K | $407.0K | $407.0K | $406.0K |
| Retained earnings | -$209.9M | -$210.1M | -$210.8M | — | -$233.5M | -$234.4M | -$233.7M | -$235.4M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98.0K | $283.0K | $2.1M | $1.9M | $520.0K | $1.2M | $1.2M | $2.1M |
| Investing cash flow | -$57.0K | -$141.0K | -$38.0K | -$117.0K | -$201.0K | — | -$129.0K | -$522.0K |
| Financing cash flow | — | — | -$1.0M | -$900.0K | -$1.0M | -$1.5M | -$1.7M | -$1.5M |
| Free cash flow | $41.0K | $142.0K | $2.1M | $1.8M | $319.0K | — | $1.1M | $1.6M |
| Capital expenditures | $57.0K | $141.0K | $38.0K | $117.0K | $201.0K | — | $129.0K | $522.0K |
| Depreciation & amortization | $127.0K | $118.0K | $118.0K | $111.0K | $101.0K | $95.0K | $95.0K | $86.0K |
| Share-based compensation | $4.0K | $4.0K | $4.0K | $16.0K | $9.0K | $15.0K | $73.0K | $86.0K |
| Deferred income taxes | — | — | -$21.3M | — | — | — | — | — |
| Change in accounts receivable | $386.0K | $276.0K | -$317.0K | -$1.3M | -$1.5M | $224.0K | $1.2M | $1.1M |
| Change in accounts payable | $374.0K | -$47.0K | -$390.0K | -$8.0K | -$470.0K | $61.0K | -$17.0K | $150.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.0M | $31.8M | $33.1M |
| Gross profit | $24.1M | $29.9M | $25.1M | $18.2M | $18.8M |
| Operating income | $4.1M | $8.1M | $4.0M | -$3.6M | -$6.3M |
| Net income | $24.6M | $6.7M | $2.0M | -$22.0M | -$14.9M |
| EPS (diluted) | $0.89 | $0.40 | $0.45 | $-5.18 | — |
| EPS (basic) | $5.55 | $1.42 | $0.45 | $-5.18 | $-3.61 |
| Operating margin | $11 | $17 | $10 | -$11 | -$19 |
| Net margin | $63 | $14 | $5 | -$69 | -$45 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|
| Total assets | $33.8M | $14.8M | $14.0M | $13.0M | $12.1M |
| Total liabilities | $11.5M | $17.0M | $18.0M | $18.7M | $20.4M |
| Stockholders' equity | $22.4M | -$2.2M | -$50.5M | -$52.3M | -$54.8M |
| Total current assets | $9.9M | $11.8M | $11.1M | $10.2M | $9.4M |
| Total current liabilities | $5.1M | $10.6M | $11.6M | $12.3M | $12.6M |
| Cash & equivalents | $2.5M | $1.5M | $2.1M | $2.0M | $2.8M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $5.6M | $8.5M | $7.3M | $6.2M | $5.0M |
| Inventory | $1.1M | $1.2M | — | — | — |
| Other current assets | $1.7M | $1.8M | $1.7M | $1.9M | $1.6M |
| Property, plant & equipment | $1.4M | $1.4M | $1.4M | $1.1M | $925.0K |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $44.0K | $45.0K | $45.0K | $45.0K | $45.0K |
| Accounts payable | $983.0K | $1.7M | $1.7M | $1.8M | $1.4M |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $5.6M | $5.2M | $5.2M | $5.1M | $5.1M |
| Common stock & paid-in capital | $407.0K | $406.0K | $406.0K | $406.0K | $406.0K |
| Retained earnings | -$210.8M | -$235.4M | -$237.3M | -$238.9M | -$241.4M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $5.8M | $4.6M | $3.8M | -$7.7M | -$8.7M |
| Investing cash flow | -$356.0K | -$876.0K | -$87.0K | $6.2M | -$315.0K |
| Financing cash flow | -$4.4M | -$5.8M | -$5.0M | $3.0M | $9.0M |
| Free cash flow | $5.5M | $3.8M | $3.3M | -$8.0M | -$9.1M |
| Capital expenditures | $356.0K | $876.0K | $470.0K | $322.0K | $354.0K |
| Depreciation & amortization | $425.0K | $300.0K | $1.0M | $2.6M | $5.4M |
| Share-based compensation | $35.0K | $291.0K | $630.0K | $1.3M | $1.3M |
| Deferred income taxes | -$21.3M | — | — | — | $38.0K |
| Change in accounts receivable | -$2.9M | $3.5M | -$227.0K | $133.0K | -$2.1M |
| Change in accounts payable | -$807.0K | $120.0K | $489.0K | -$735.0K | -$1.8M |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IDXG as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2020-07-29 to 2026-08-20
Recent transactions
- Most recent: Burnell Thomas W. (CEO, President & Chairman) — Option exercise of 1,966,763 shares on 2026-08-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Burnell Thomas W. | CEO, President & Chairman | Option exercise | 2026-08-20 | 1,966,763 |
| McCarthy Christopher | CFO & COO | Option exercise | 2026-08-20 | 277,009 |
| 1315 Capital II, L.P. | 10% owner | Derivative conversion | 2026-01-20 | 9,405,941 |
| Ampersand 2018 Limited Partnership | 10% owner | Derivative conversion | 2026-01-20 | 13,861,386 |
| Freeburg Thomas John | Chief Financial Officer | Grant / award | 2021-03-10 | 50,000 |
| Kamin Peter | 10% owner | Open market purchase | 2021-03-01 | 16,360 |
| Gorman Robert J. | Director | Grant / award | 2021-01-29 | 12,438 |
| Early James | Former Chief Financial Officer | Option exercise | 2020-07-29 | 5,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-20 | Burnell Thomas W. | CEO, President & Chairman | Option exercise | 1,966,763 | $0.00 |
| 2026-08-20 | Burnell Thomas W. | CEO, President & Chairman | Tax withholding | 581,718 | $1.61 |
| 2026-08-20 | McCarthy Christopher | CFO & COO | Option exercise | 277,009 | $0.00 |
| 2026-01-20 | 1315 Capital II, L.P. | 10% owner | Derivative conversion | 9,405,941 | $2.02 |
| 2026-01-20 | Ampersand 2018 Limited Partnership | 10% owner | Derivative conversion | 13,861,386 | $2.02 |
| 2024-12-01 | McCarthy Christopher | Chief Financial Officer | Option exercise | 1,111 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-08-27 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-12 | View on SEC.gov → |
Recent news
Headlines about IDXG (INTERPACE BIOSCIENCES INC). Links open the publisher — we don’t host full articles.
-
Diluted shares outstanding of Interpace Biosciences, Inc. – GETTEX:PF4
TradingView · 2026-10-16 -
IDXG 8-K & SEC Filings
Yahoo Finance · 2026-10-16 -
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Yahoo · 2026-10-15 -
Interpace Biosciences announces 1-for-5 reverse stock split
Seeking Alpha · 2026-08-26 -
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Yahoo Finance · 2026-08-26 -
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Yahoo Finance · 2026-08-10 -
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Yahoo Finance · 2026-05-12 -
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
Yahoo Finance · 2026-03-30
No headlines in this category right now — try “All”.